Piramal Pharma reported a revenue beat in the first quarter of FY27, supported by a recovery in its CDMO segment. While the company still works toward achieving annual profitability, brokerages have noted improved operational performance. Investors should track the timeline for converting new project proposals into firm commercial contracts.
Piramal Pharma has shown signs of operational recovery in the first quarter of the 2027 fiscal year, with performance metrics exceeding previous analyst expectations. The company reported a 7% revenue beat and a 41% outperformance in EBITDA, which is a measure of operating profit. Notably, these results were achieved despite a net loss, which was reported to be lower than earlier estimates due to higher other income.
CDMO Segment Performance
A primary driver of the company’s recent activity is its Contract Development and Manufacturing Organization (CDMO) segment. This business unit provides drug development and manufacturing services to global pharmaceutical companies. After four consecutive quarters of year-over-year declines, the segment showed a revival in the first quarter of FY27. This turnaround was driven by operational execution across the company’s manufacturing facilities in India and abroad.
While the return to growth in the CDMO segment is a significant development, the company continues to face a specific operational hurdle. Management has indicated that the time taken by clients to turn requests for proposals into confirmed commercial orders remains longer than usual. This means that while interest in their services exists, the actual conversion of these inquiries into revenue-generating projects is taking more time than in previous periods.
Financial Trajectory and Projections
Following a loss in the previous fiscal year, the path to sustained profitability remains a central theme for the company. Projections suggest that Piramal Pharma is moving toward a profit after tax of INR 1.1 billion for FY27, with further growth to INR 3 billion anticipated in FY28. These estimates are based on the assumption that the CDMO segment’s recovery will continue and that operational efficiencies will improve as the company scales its activities.
Investors may monitor the company’s ability to shorten these client decision-making timelines, as this is critical for hitting future revenue targets. Additionally, the sustainability of profit margins will be a key focus in upcoming quarterly filings, as the company works to transition from the losses recorded in recent periods toward stable annual earnings.